



Seale & Associates

HEALTHCARE INDUSTRY
Q3 2023
VALUATION UPDATE

Introduction

We are pleased to share our Healthcare Industry Multiples Valuation Update for Q3 2023.

At Seale & Associates, we are committed to providing process-driven solutions designed to optimize value and achieve our client's strategic objectives in a range of transactions, including **Mergers, Acquisitions, Divestitures and Carve-Outs, Business Sales, Recapitalizations, and Joint Ventures**, among other corporate finance and strategy consulting services.

Over the course of 25+ years, we have successfully served clients all over the world, and we are delighted to continue providing investment banking advisory services to our Healthcare Industry clients who are looking to grow through acquisitions or optimize their portfolios through strategic divestitures.

Seale has extensive experience advising leading multinational companies, private equity firms, and family-owned businesses across a wide range of industries.



James A. Seale | President

jseale@sealeassociates.com



Brett M. Carmel | Senior Managing Director

bcarmel@sealeassociates.com



Robert Whitney | Managing Director

rwhitney@sealeassociates.com



Sergio Garcia del Bosque | Managing Director

sgarcia@sealeassociates.com



Carlos Hernández | Managing Director

chernandez@sealeassociates.com



Alejandro Montemayor | Vice President


amontemayor@sealeassociates.com

Healthcare's Industry Overview, M&A Trends and Market Intelligence


Healthcare's Industry Overview

- The global **healthcare** services market size was valued at **US\$10.3T** in **2021** and is projected to reach **US\$21.1T** by **2030**, growing at a **CAGR** of **8.27%** from 2023 to 2030
- The **pharmaceutical** manufacturing market is expected to register a **CAGR** of more than **11 %** over the forecast period, 2022-2027
- The **medical devices market** size is expected to grow from **US\$595.4B** in **2023** to **US\$834.7B** by **2028**, at a **CAGR** of **6.99%** during the forecast period (2023-2028)
- **COVID-19** significantly impacted the Pharmaceutical Manufacturing and OTC Drugs markets, since it **increased** the **demand** for **medications**, including vaccines and other drug types
- Hospital **equipment** for the management of **COVID-19**, like ventilators, experienced a **surge** in sales to fulfill the overwhelming demand, whilst the demand for **other medical devices**, such as radiological equipment, **decreased**
- The growing **burden** of **chronic** diseases and the **senior** population is driving the **demand** for pharmaceutical manufacturing
- The **E-pharmacy** Market has witnessed **drastic** growth since the COVID-19 **pandemic**, due to an increased dependence on online pharmacies to purchase both OTC and prescription drugs

Healthcare's Industry M&A Deal Size and Volume



Healthcare's Industry M&A Average EV/EBITDA and EV/Revenue






Pharmaceutical Producers Global Comparable Public Companies (1/3)

Company	Country	Market Cap. US\$M	Enterprise Value US\$M	Revenue US\$M	EBITDA Margin	Annual Average EV/EBITDA		Third Quarter Sep. 30, 2023		
						2021	2022	EV/EBITDA	EV/Revenue	
AbbVie Inc.		USA	\$263,098	\$315,757	\$55,138	53.6%	11.1x	11.2x	10.7x	5.7x
Astellas Pharma Inc.		JPN	\$24,895	\$23,278	\$10,201	22.2%	10.6x	11.0x	10.3x	2.3x
AstraZeneca PLC		GBR	\$209,979	\$233,992	\$44,994	39.7%	25.3x	21.7x	13.1x	5.2x
Bausch Health Companies Inc.		CAN	\$2,995	\$23,902	\$8,542	33.3%	10.1x	8.3x	8.4x	2.8x
Bristol-Myers Squibb Company		USA	\$121,252	\$151,788	\$44,935	42.2%	9.1x	8.9x	8.0x	3.4x
Catalent, Inc.		USA	\$8,208	\$12,777	\$4,223	11.7%	25.5x	16.6x	25.8x	3.0x
Daiichi Sankyo Company, Limited		JPN	\$52,709	\$48,706	\$9,353	12.8%	36.2x	45.3x	40.7x	5.2x
Eisai Co., Ltd.		JPN	\$15,958	\$15,208	\$5,084	12.8%	19.4x	37.5x	23.4x	3.0x
Eli Lilly and Company		USA	\$483,038	\$498,559	\$32,073	30.9%	24.3x	28.6x	50.3x	15.5x
GSK plc		GBR	\$73,781	\$91,400	\$36,185	33.3%	9.6x	8.8x	7.6x	2.5x

Pharmaceutical Producers Global Comparable Public Companies (2/3)

Company	Country	Market Cap. US\$M	Enterprise Value US\$M	Revenue US\$M	EBITDA Margin	Annual Average EV/EBITDA		Third Quarter Sep. 30, 2023		
						2021	2022	EV/EBITDA	EV/Revenue	
Johnson & Johnson		USA	\$404,790	\$423,147	\$97,301	35.6%	15.0x	14.0x	12.2x	4.3x
Merck & Co., Inc.		USA	\$261,238	\$291,820	\$59,315	21.3%	11.4x	11.1x	23.0x	4.9x
Novartis AG		CHE	\$212,302	\$229,281	\$54,217	37.5%	11.6x	6.2x	11.3x	4.2x
Novo Nordisk A/S		DNK	\$408,491	\$406,973	\$30,423	43.7%	21.3x	25.1x	30.6x	13.4x
Otsuka Holdings Co., Ltd.		JPN	\$19,304	\$17,499	\$13,062	17.3%	7.7x	9.3x	7.8x	1.3x
Pfizer Inc.		USA	\$187,276	\$208,439	\$77,943	41.8%	13.3x	7.6x	6.4x	2.7x
Roche Holding AG		CHE	\$220,936	\$245,938	\$69,046	36.9%	12.5x	12.2x	9.7x	3.6x
Sanofi		FRA	\$134,651	\$148,783	\$48,369	31.4%	10.4x	10.5x	9.8x	3.1x
Shionogi & Co., Ltd.		JPN	\$13,088	\$9,439	\$3,391	41.6%	13.9x	17.6x	6.7x	2.8x
Sun Pharmaceutical Industries Limited		IND	\$33,460	\$32,868	\$5,573	26.7%	19.1x	20.6x	22.1x	5.9x





Pharmaceutical Producers Global Comparable Public Companies (3/3)

Company	Country	Market Cap. US\$M	Enterprise Value US\$M	Revenue US\$M	EBITDA Margin	Annual Average EV/EBITDA		Third Quarter Sep. 30, 2023		
						2021	2022	EV/EBITDA	EV/Revenue	
Takeda Pharmaceutical Company Limited		JPN	\$48,304	\$81,290	\$27,814	30.7%	10.6x	8.6x	9.5x	2.9x
Teva Pharmaceutical Industries Limited		ISR	\$11,431	\$30,434	\$15,273	25.3%	7.5x	7.0x	7.9x	2.0x
UCB SA		BEL	\$15,570	\$18,152	\$5,410	23.1%	12.4x	11.2x	14.5x	3.4x
■ Excluded from mean and median						Mean	12.5x	12.4x	12.4x	3.5x
						Median	12.4x	11.2x	10.7x	3.4x









Medical Devices & Consumables Global Comparable Public Companies (1/2)

Company	Country	Market Cap. US\$M	Enterprise Value US\$M	Revenue US\$M	EBITDA Margin	Annual Average EV/EBITDA		Third Quarter Sep. 30, 2023		
						2021	2022	EV/EBITDA	EV/Revenue	
Ansell Limited		AUS	\$1,785	\$2,124	\$1,655	16.5%	11.3x	8.0x	7.8x	1.3x
Atrion Corporation		USA	\$727	\$725	\$169	26.4%	25.2x	21.7x	16.3x	4.3x
Baxter International Inc.		USA	\$19,112	\$34,373	\$15,280	21.4%	15.1x	14.8x	10.5x	2.2x
Becton, Dickinson and Company		USA	\$75,002	\$90,853	\$19,372	25.9%	15.6x	16.1x	18.1x	4.7x
Boston Scientific Corporation		USA	\$77,311	\$86,598	\$13,757	25.3%	25.5x	20.9x	24.9x	6.3x
Cardinal Health, Inc.		USA	\$21,388	\$22,615	\$210,172	1.2%	7.0x	7.8x	8.7x	0.1x
ConvaTec Group PLC		GBR	\$5,403	\$6,737	\$2,084	22.4%	16.1x	15.8x	14.4x	3.2x
Edwards Lifesciences Corporation		USA	\$42,116	\$41,362	\$5,819	30.8%	39.8x	32.9x	23.0x	7.1x
Hogy Medical Co.,Ltd.		JPN	\$519	\$451	\$263	26.5%	7.5x	7.3x	6.5x	1.7x
ICU Medical, Inc.		USA	\$2,872	\$4,365	\$2,249	13.8%	17.8x	21.5x	14.1x	1.9x

Medical Devices & Consumables Global Comparable Public Companies (2/2)

Company	Country	Market Cap. US\$M	Enterprise Value US\$M	Revenue US\$M	EBITDA Margin	Annual Average EV/EBITDA		Third Quarter Sep. 30, 2023		
						2021	2022	EV/EBITDA	EV/Revenue	
JMS Co.,Ltd.		JPN	\$88	\$173	\$435	6.5%	5.9x	6.2x	6.1x	0.4x
Medtronic plc		IRL	\$104,261	\$121,504	\$31,558	27.3%	23.3x	14.5x	14.1x	3.9x
Merit Medical Systems, Inc.		USA	\$3,978	\$4,313	\$1,226	16.8%	23.0x	18.0x	20.9x	3.5x
Owens & Minor, Inc.		USA	\$1,237	\$3,586	\$10,229	4.6%	8.3x	8.5x	7.7x	0.4x
Sewoon Medical Co., Ltd		KOR	\$84	\$37	\$50	27.3%	10.8x	5.6x	2.7x	0.7x
Stryker Corporation		USA	\$103,782	\$115,739	\$19,885	24.9%	25.2x	21.2x	23.4x	5.8x
Teleflex Incorporated		USA	\$9,230	\$10,607	\$2,899	28.1%	27.4x	17.3x	13.0x	3.7x
West Pharmaceutical Services, Inc.		USA	\$27,713	\$27,228	\$2,927	30.0%	39.2x	25.0x	31.0x	9.3x
■ Excluded from mean and median						Mean	16.6x	14.1x	13.0x	2.5x
						Median	16.9x	15.9x	14.1x	3.4x



Drug Stores Global Comparable Public Companies

Company	Country	Market Cap. US\$M	Enterprise Value US\$M	Revenue US\$M	EBITDA Margin	Annual Average EV/EBITDA		Third Quarter Sep. 30, 2023		
						2021	2022	EV/EBITDA	EV/Revenue	
Corporativo Fragua, S.A.B. de C.V.		MEX	\$2,725	\$2,522	\$6,145	5.1%	8.9x	6.8x	8.1x	0.4x
CVS Health Corporation		USA	\$89,677	\$155,202	\$346,601	6.2%	8.5x	8.8x	7.2x	0.4x
Dimed S.A. Distribuidora de Medicamentos		BRA	\$349	\$510	\$866	5.8%	17.8x	11.6x	10.1x	0.6x
Empreendimentos Pague Menos S.A.		BRA	\$270	\$959	\$2,201	5.9%	10.8x	7.8x	7.4x	0.4x
Farmacias Benavides, S.A.B. de C.V.		MEX	\$423	\$602	\$982	11.2%	8.0x	4.4x	5.5x	0.6x
Raia Drogasil S.A.		BRA	\$9,481	\$10,680	\$6,585	10.3%	20.9x	15.3x	15.7x	1.6x
Rite Aid Corporation		USA	\$25	\$6,065	\$23,475	4.6%	5.5x	5.3x	5.6x	0.3x
Walgreens Boots Alliance, Inc.		USA	\$19,199	\$64,106	\$139,081	5.2%	10.3x	7.8x	8.8x	0.5x
■ Excluded from mean and median						Mean	8.7x	7.5x	7.5x	0.5x
						Median	9.6x	7.8x	7.8x	0.5x

Pharmaceutical Products – Q3 Global Transactions

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	EV/ Revenue
Sep-23	 Slayback Pharma	USA	Develops complex generic and specialty pharmaceutical drugs and products		Multiple Sellers	100.0%	-	-	-
Sep-23	Sanofi's CNS brands	BRA	Consist in brands intended for four CNS disorders: anxiolytic, psycholeptic, anti-epileptic and anti-psychotic			100.0%	-	-	-
Sep-23	Nestlé's Palforzia Business	CHE	Produces peanut allergy medicine intended for children			100.0%	-	-	-
Aug-23	 Mindset	CAN	Develops psychedelic medicines to treat neurological and psychiatric disorders		-	100.0%	\$59.1	-	9.6x
Aug-23	Topical Lamisil Business of Haleon UK Holdings Ltd.	GBR	Treats fungal infections like Athlete's foot			100.0%	\$298.5	-	3.6x
Jul-23	Santhera's Raxone / Idebenone Business Worldwide	CHE	Comprises idebenone medicine for the treatment of patients with Leber's hereditary optic neuropathy (LHON)			100.0%	-	-	-
Jul-23	 REATA	USA	Develops therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases		-	100.0%	\$7,300.0	-	-
Jul-23	 Palette	SWE	Develops and provides products for local pain relief in obstetrics and gynecology		-	100.0%	\$650.0	-	-
Jul-23	Traverse's Bile Acid Product Portfolio	USA	Comprises Cholbam, a treatment for bile acid synthesis disorders, and Chenodal, a treatment for radiolucent stones in the gallbladder			100.0%	\$445.0	-	-
Jul-23	Wellstat Therapeutics' Vistogard and Xuriden Products	USA	Develops treatments for patients following fluorouracil (5-FU) or capecitabine overdose, and patients with hereditary orotic aciduria (HOA) (ii), respectively		Wellstat Therapeutics Corporation	100.0%	-	-	-
Jul-23	 FIS	ITA	Develops and manufactures small molecule active pharmaceutical ingredients (APIs) and intermediate		Nine Trees Group S.p.A.	100.0%	-	-	-
							Mean	-	6.6x
							Median	-	6.6x

Medical Equipment – Q3 Global Transactions

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	EV/ Revenue
Sep-23		USA	Designs and manufactures medical devices and implants		-	100.0%	-	-	-
Sep-23		GBR	Designs and manufactures bariatric equipment		-	100.0%	-	-	-
Sep-23		USA	Specializes in diagnosing and treating chronic low back pain		-	100.0%	\$850.0	-	-
Sep-23		CAN	Designs and manufactures tilt-in-space and bariatric wheelchairs intended to improve posture and function and provide skin protection for individuals		-	100.0%	-	-	-
Sep-23		IRL	Manufactures and distributes medical devices for pelvic floor muscle strengthening and nerve stimulation		-	100.0%	-	-	-
Aug-23		USA	Provides anti-gravity systems for use in physical and neurological rehabilitation		-	100.0%	\$19.0	-	1.0x
Aug-23		USA	Develops an optical system designed for sequencing and protein detection		-	100.0%	\$110.0	-	-
Jul-23		DEU	Manufactures metal products for medical technology		IK Partners	100.0%	\$408.0	-	-
Jul-23		SWE	Develops mobile x-ray technology		Verso	100.0%	-	-	-
Jul-23		USA	Develops, manufactures, and markets in vitro diagnostic products		ONE ROCK CAPITAL PARTNERS	100.0%	-	-	-
Jul-23		FRA	Develops Simeox, a technology enabled breathing apparatus		-	100.0%	\$45.0	-	-
							Mean	-	1.0x
							Median	-	1.0x

Drug Stores – Q3 Global Transactions

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	EV/ Revenue
Aug-23	McGovern's Pharmacy in Derrylin	GBR	Operates a pharmacy store	Local pharmacist, Neil McConnell	-	100.0%	-	-	-

Hospitals – Q3 Global Transactions

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	EV/ Revenue
Sep-23	 BEACON POINT RECOVERY CENTER	USA	Operates a drug and alcohol addiction treatment center	 PRAESUM HEALTHCARE	-	100.0%	-	-	-
Sep-23	 MASEFIELD VETERINARY CENTRE	GBR	Operates as a veterinary clinic	 CVS Group plc Passionate about animal care	-	100.0%	\$3.8	-	-
Sep-23	Assets of Aurelia Hospital	ITA	Comprises multi-specialist health facilities authorized to carry out medical-surgical and rehabilitation services	 GHC GRANDIHEALTHCARE	 Aurelia Hospital	100.0%	\$50.4	-	-
Sep-23	Beverly Community Hospital Association Inc.	USA	Owens and operates an acute care facility	 Adventist Health	-	100.0%	-	-	-
Sep-23	 LA FUENTE POST ACUTE	USA	Operates a nursing facility offering post-acute care services	 CARETRUST E.I.T.	-	100.0%	-	-	-
Aug-23	Four Nursing Facilities in West Virginia	USA	Comprises nursing facilities	 OMEGA Healthcare INVESTORS, INC.	-	100.0%	\$114.8	-	-
Aug-23	 FOUNTAIN VIEW AT LOGAN SQUARE	USA	Comprises living apartments, personal care apartments and beds for nursing care	 TRYKO PARTNERS	-	100.0%	\$55.6	-	-
Jul-23	Bravera Health Brooksville, Bravera Health Spring Hill and Bravera Health Seven Rivers	USA	Operate hospitals that provide healthcare services including surgeries, emergency medical care, cardiac care, laboratory services, and orthopedic services	 TGH Tampa General Hospital	-	100.0%	-	-	-

Selected Transactions Commentary



“Through this acquisition, we are not only building depth in geography, but we’re also bringing in products that have a clear synergy with our existing portfolio and the core sub-therapy focuses of mental health and epilepsy, where there continues to be significant unmet need.”

James Burt, CEO of Pharmanovia



“Teleflex is an excellent fit for our products and team. The synergies between the companies’ portfolios, specifically within the urology call point, create an exciting opportunity for continued high growth and market access expansion.”

Per Langoe, CEO and Co-Founder of Palette Life Sciences



“The acquisition will reinforce our well-established reputation for excellence and our ability to cultivate enduring partnerships, aligning seamlessly with Klingel’s similar ethos.”










Stefano Alfonsi, CEO and President of Elos Medtech



“Securing this agreement is an important step for the business, as we sharpen our focus on the commercialization of vamorolone in Europe, subject to approval. We look forward to seeing Chiesi’s progress over the coming months and years for the benefit of patients worldwide.”

Dario Eklund, CEO of Santhera

Private Equity Transactions

INDUSTRY CLASIFICATION	PERIOD	AVERAGE ENTERPRISE VALUE (IN USD)	REVENUE (IN USD)	TTM REVENUE GROWTH	ENTERPRISE VALUE / REVENUE	EBITDA MARGIN	ENTERPRISE VALUE /EBITDA	NUMBER OF TRANSACTIONS
 Health and Personal Care Stores <i>NAICS 4461 – Health and Personal Care Stores</i>	 2022-2023	 \$96.0M	 \$56.2M	 34.7%	 1.6x	 21.7%	 7.8x	 3
Home Health Care Services <i>NAICS 621610 – Home Health Care Services</i>	2021-2022	\$27.3M	\$19.2M	11.3%	1.5x	18.9%	8.0x	12

Notes:

- Data obtained via GF Data, a subscription-based information platform, offering detailed information and metrics about the transactions of Private Equity funds in the U.S.
- The data is provided under a blind confidential format. Users of the data are unable to identify the exact company and transaction corresponding to the transaction details. Given this blind approach, the data submitted is less likely to be biased or manipulated.

INVEKRA

TARGET

Laboratorios Portugal S.R.L

TRANSACTION TYPE

Acquisition Advisory

INDUSTRIES

Healthcare,
Pharmaceutical

GEOGRAPHY

Peru

SITUATION

Seale & Associates acted as exclusive financial advisor to Invekra, assisting with comprehensive research on the Peruvian pharmaceutical market and the prioritization of potential acquisition targets.

SEALE & ASSOCIATES' APPROACH

Seale completed a thorough screening of the potential universe of pharmaceutical companies that would align with Invekra's strategy. Seale pre-qualified each potential target and initiated transaction discussions with the targets that best fit Invekra's strategy and investment criteria.

OUTCOME

The process resulted in a successful acquisition of Laboratorios Portugal S.R.L by Invekra, a conglomerate of 12 Latin American pharmaceutical companies. The acquisition strengthens Invekra's presence in Latin America.

“This acquisition strengthens Invekra’s presence in one of the fastest growing markets in Latin America”



“This acquisition strengthens Invekra’s presence in one of the fastest growing markets in Latin America.”

Carlos Hernández, Managing Director at Seale & Associates

CONVATEC

TARGET

Sensi-Care and Aloe Vesta

TRANSACTION TYPE

Sell-side Advisory

INDUSTRIES

Healthcare, Personal Care

GEOGRAPHY

Reading, GBR

SITUATION

Seale & Associates acted as financial advisor to ConvaTec Group (LON: CTEC) on the divestiture of Sensi-Care and Aloe Vesta to Medline Industries. ConvaTec Group (LON: CTEC), is a global medical products company based in the United Kingdom.

SEALE & ASSOCIATES' APPROACH

Seale managed a competitive auction process with potential strategic and financial buyers for Sensi-Care and Aloe Vesta. Seale's disciplined approach allowed our client to maintain momentum, negotiating leverage throughout the process and ensure closing at a premium value and more favorable terms.

OUTCOME

The process resulted in a successful acquisition of Sensi-Care and Aloe Vesta by Medline Industries, a healthcare company with almost USD\$14 billion in annual sales. The divestiture is part of ConvaTec's strategy to focus on its core businesses and markets.

“Seale was instrumental in keeping the process moving in a swift, orderly fashion”



“Seale was instrumental in keeping the process moving in a swift, orderly fashion. Their common sense and ability to find simple, common ground solutions while preserving our interests were invaluable in bringing this project to a successful conclusion.”

George Landau, Vice President of Corporate Development at ConvaTec

Sign up for M&A insights

One of our core capabilities is to deliver sector-specific intelligence designed specifically for industry leaders, private equity firms, and their advisors. Our industry reports and featured articles deliver real-time access to key industry data, including:



Emerging industry trends

Quarterly reports covering 30+ industries

Monthly reports for the U.S., Mexico, and Colombia

Analysis of transactions and market trends

Valuable insights for industry leaders

Receive email updates with our proprietary data, reports, and insights as they're published for the industries that matter to you the most

SUBSCRIBE

Representative Global Engagements

 <p>INMAGUSA Grupo Galaz, S.A de C.V.</p> <p>has been acquired by</p> 	 <p>has sold</p>  <p>to</p> 	 <p>has sold its Sanitaryware business units ST. THOMAS CREATIONS and VITROMEX to </p>	 <p>has sold</p>  <p>to</p> 	 <p>has sold</p>  <p>to</p> 	 <p>has been acquired by</p> 	  <p>acquired</p> <p>The Zinc Recycling Business of</p> 
 <p>acquired</p>  <p>Automotive dealerships from</p> 	 <p>has sold</p>  <p>to</p> 	 <p>has sold</p> <p>Kidde de Mexico, S.A. de C.V. Fire Safety Solutions Business</p> <p>to an affiliate of</p> 	 <p>has sold its concrete pumping business</p> <p>to</p> 	<p>CORPORACION </p> <p>has sold</p>  <p>to</p> 	 <p>has been acquired by</p> 	 <p>has been acquired by</p> 
 <p>has been acquired by</p> 	<p>intelectiva®</p> <p>has acquired</p>  <p>KFC Costa Rica from</p> 	 <p>Multiple acquisitions</p> 	 <p>has partnered with</p>  <p>a subsidiary of</p> 	 <p>has been acquired by</p> 	 <p>has merged its Beverage Division with</p> 	 <p>has merged its Beverage Division with</p> 

Advisor to Leading Companies Worldwide



Headquarters

901 N. Glebe Road
5th Floor
Arlington, Virginia



Mexico City Office

Av. Javier Barros Sierra 495
3rd Floor
Park Plaza III
Mexico City, Mexico



Monterrey Office

Av. Lázaro Cárdenas 2225
3rd Floor
San Pedro Garza García, N.L.

Please contact us if you would like further information about M&A trends and/or specific transaction multiples for your industry

© Seale & Associates

Washington, D.C. | Miami | Cincinnati | Mexico City | Monterrey

Creative Solutions. Trusted Advice.

For over 25 years, Seale & Associates has served leading public and private companies from around the world and operating in a broad range of industries with a high level of quality, integrity and independence while presenting innovative ideas and trusted solutions to address their most complex dealings.

25

YEARS OF EXPERIENCE

\$50B+

TRANSACTIONS GLOBALLY

SERVICES AND SOLUTIONS

Mergers & Acquisitions

Divestitures

Joint Ventures / Alliances

Recapitalizations

Due Diligence / Support

Expert Witness Testimony

Corporate Finance Advisory

Strategy Consulting

Trusted Advisor to Leading Companies Worldwide

We have worked repeatedly with many of the most well-known companies in the world...

...as well as with reputable funds, family-offices and privately held companies.



Seale & Associates

Creative Solutions. Trusted Advice.